Roles of AKR1C3 in malignancy

被引：6
作者：
Xiao, Xin-Zhu [1 ]
Lin, Li-Ying [1 ]
Zhuang, Ming-Kai [1 ]
Zhong, Can-Mei [1 ]
Chen, Feng-Lin [1 ]
机构：
[1] Fujian Med Univ, Union Hosp, Dept Gastroenterol, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2021年 / 134卷 / 09期
关键词：
PROSTATE-CANCER; GROWTH;
D O I：
10.1097/CM9.0000000000001379
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1052 / 1054
页数：3
相关论文
共 50 条
  • [41] Screening, synthesis, crystal structure, and molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as novel AKR1C3 inhibitors
    Zheng, Xuehua
    Jiang, Zan
    Li, Xiaolin
    Zhang, Chen
    Li, Zhe
    Wu, Yinuo
    Wang, Xinhua
    Zhang, Chao
    Luo, Hai-bin
    Xu, Jun
    Wu, Deyan
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (22) : 5934 - 5943
  • [42] Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer
    Wenners, Antonia
    Hartmann, Felix
    Jochens, Arne
    Roemer, Anna Maria
    Alkatout, Ibrahim
    Klapper, Wolfram
    van Mackelenbergh, Marion
    Mundhenke, Christoph
    Jonat, Walter
    Bauer, Maret
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (03) : 548 - 556
  • [43] Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
    Kafka, Mona
    Mayr, Fabian
    Temml, Veronika
    Moeller, Gabriele
    Adamski, Jerzy
    Hofer, Julia
    Schwaiger, Stefan
    Heidegger, Isabel
    Matuszczak, Barbara
    Schuster, Daniela
    Klocker, Helmut
    Bektic, Jasmin
    Stuppner, Hermann
    Eder, Iris E.
    CANCERS, 2020, 12 (08) : 1 - 18
  • [44] Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review
    Penning, Trevor M.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2017, 27 (12) : 1329 - 1340
  • [45] Modeling Single Nucleotide Polymorphisms in the Human AKR1C1 and AKR1C2 Genes: Implications for Functional and Genotyping Analyses
    Arthur, Jonathan W.
    Reichardt, Juergen K. V.
    PLOS ONE, 2010, 5 (12):
  • [46] New enzymatic assay for the AKR1C enzymes
    Beranic, Natasa
    Stefane, Bogdan
    Brus, Boris
    Gobec, Stanislav
    Rizner, Tea Lanisnik
    CHEMICO-BIOLOGICAL INTERACTIONS, 2013, 202 (1-3) : 204 - 209
  • [47] Coumarin-Based Aldo-Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors
    Jonnalagadda, Sravan K.
    Duan, Ling
    Dow, Louise F.
    Boligala, Geetha P.
    Kosmacek, Elizabeth
    McCoy, Kristyn
    Oberley-Deegan, Rebecca
    Chhonker, Yashpal Singh
    Murry, Darryl J.
    Reynolds, C. Patrick
    Maurer, Barry J.
    Penning, Trevor M.
    Trippier, Paul C.
    CHEMMEDCHEM, 2024, 19 (21)
  • [48] Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes
    Alshogran, Osama Y.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (10) : 1063 - 1073
  • [49] Role of human type 3 3α-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells
    Rizner, TL
    Lin, HK
    Penning, TM
    CHEMICO-BIOLOGICAL INTERACTIONS, 2003, 143 : 401 - 409
  • [50] AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer
    Zhu, Hong
    Chang, Lin-Lin
    Yan, Fang-Jie
    Hu, Yan
    Zeng, Chen-Ming
    Zhou, Tian-Yi
    Yuan, Tao
    Ying, Mei-Dan
    Cao, Ji
    He, Qiao-Jun
    Yang, Bo
    THERANOSTICS, 2018, 8 (03): : 676 - 692
12345